The European Commission's investigation centers on allegations that Sanofi engaged in deceptive marketing practices to promote its Efluelda flu vaccine while undermining a competitor's product, Fluad, produced by CSL Seqirus.
This inquiry is particularly significant as Sanofi holds a dominant market position in both France and Germany, raising concerns about fair competition in the pharmaceutical sector.
The investigation follows unannounced raids on Sanofi's offices in September 2025, during which the company expressed confidence in its compliance with regulations and indicated a willingness to cooperate with the Commission. The outcome of this investigation could have substantial implications for Sanofi's operations and reputation in the European market